Vietnam Vaccine Joint Stock Company (VNVC) has signed a contract with Germany’s Rieckermann Group, a global leader in the design of vaccine and pharmaceutical plants, to develop a cutting-edge vaccine and biopharmaceutical production facility.
The new plant represents a significant investment of around USD 78.7 million. Designed and built by Rieckermann Group, the facility will be the first vaccine factory in Vietnam to meet the Leadership in Energy & Environmental Design (LEED) standards, achieving the goal of reducing Vietnam’s total greenhouse gas emissions to zero by 2050.
The 26,000 sqm complex will feature production zones for vaccines and biopharmaceuticals, as well as an animal breeding and research building, alongside other utility areas. The design will adhere to the highest international standards. The plant will comply with strict GMP (Good Manufacturing Practice) standards from the EU, FDA, PIC/S, and WHO.
Additionally, a specialized animal laboratory will facilitate pre-clinical and clinical trials for vaccines and biopharmaceuticals, ensuring compliance with GLP (Good Laboratory Practice) and AAALAC (Association for Assessment and Accreditation of Laboratory Animal Care) standards, which uphold legal and ethical requirements.
Rieckermann is renowned for designing facilities for major global companies such as GSK, MSD, and Roche, meeting the highest pharmaceutical production standards including EU GMP, FDA, PIC/S, and WHO guidelines.
(Source: VNEconomy)
